Baird Venture Partners

Partners Jim Pavlik and Benedict Rocchio lead investment decisions at BVP. The partnership committee operates within Baird Capital's broader private markets structure, which manages over $4 billion in assets across venture, growth equity, and buyouts. Investment decisions integrate BVP's venture team with Baird's sector-specific equity research and investment banking colleagues.

BVP sources deals through Baird's middle-market investment banking network, which executes over 300 transactions annually across technology, healthcare, and industrial sectors. The platform also routes deals through Baird's 130 equity research analysts covering more than 800 public companies. That dual channel — private M&A plus public-company research — surfaces companies at the point where they outgrow angel capital and require institutional venture backing.

BVP targets Series A and Series B rounds, typically writing initial checks between $5 million and $15 million. The partnership reserves significant capital for follow-on investments through subsequent rounds. BVP concentrates on B2B enterprise software, digital health, fintech, AI/ML, cybersecurity, and industrial technology companies, primarily in North America.

Baird Venture Partners is the early-stage venture arm of Baird Capital, which is the private equity and venture capital platform of Baird, the employee-owned international financial services firm. In January 2022, Baird consolidated all venture activities under the Baird Capital brand, unifying BVP with Baird Capital's growth equity and buyout investment teams. The collective platform manages over $4 billion in committed capital.

BVP sits inside an employee-owned partnership (Baird) founded in 1919, where investment professionals hold meaningful equity in the parent company. That structure links venture fund returns to the broader firm’s multi-decade partnership horizon, incentivizing patient capital deployment rather than rapid fund-cycle turnover. BVP also draws on Baird's 5,000-person platform — including investment banking, equity research, and private equity — for deal origination, due diligence, and portfolio support that standalone firms must build independently.

BVP does not invest in consumer-focused startups, hardware, therapeutics, medical devices, or deep biotechnology. The partnership has historically concentrated on B2B technology and healthcare services models where Baird's investment banking and equity research franchises provide sector-specific advantages in sourcing and diligence. Consumer internet and hard-science life sciences fall outside that overlap.

BVP leads and co-leads rounds alongside syndicate partners, leveraging Baird's relationships with other venture capital firms across the Midwest, Southeast, and coastal technology corridors. The partnership does not operate a fund-of-funds or LP allocation program — it deploys capital directly into portfolio companies through equity investments. Co-investment dynamics are shaped by BVP's willingness to lead rounds and reserve follow-on capital, making it an anchor investor in select early-stage syndicates.